South Korea's Hanmi Pharmaceutical has licensed long-acting GLP/GCG analog diabetes and obesity candidate HM12525A to Janssen Pharmaceuticals, showcasing a dealmaking spree this year with major drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback